Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 8905 results

  1. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development Reference number: GID-TA10904 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  2. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  3. Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [ID6420]

    In development Reference number: GID-TA11478 Expected publication date:  12 February 2026

    Technology appraisal guidance
    In development

  4. Type 2 diabetes in adults: management (medicines update)

    In development Reference number: GID-NG10336 Expected publication date:  18 February 2026

    NICE guideline
    In development

  5. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date:  18 February 2026

    Technology appraisal guidance
    In development

  6. Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]

    In development Reference number: GID-TA11630 Expected publication date:  18 February 2026

    Technology appraisal guidance
    In development

  7. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development Reference number: GID-HST10054 Expected publication date:  20 February 2026

    Highly specialised technologies guidance
    In development

  8. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation

    In development Reference number: GID-IPG10416 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  9. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  10. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  11. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  12. Blood transfusion - Tranexamic acid (update)

    In development Reference number: GID-NG10441 Expected publication date:  26 February 2026

    NICE guideline
    In development

  13. Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]

    In development Reference number: GID-TA11201 Expected publication date:  26 February 2026

    Technology appraisal guidance
    In development

  14. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

    Quality standard
    In development

  15. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

    NICE guideline
    Last updated
    2 October 2023

    Sections for NG127